A phase II study of cisplatin, vindesine and continuously infused 5-fluorouracil in the treatment of advanced non-small-cell lung cancer. Osaka Lung Cancer Chemotherapy Study Group.

Fifty-two previously untreated patients with advanced non-small-cell lung cancer (NSCLC) were treated on a 14 day cycle with cisplatin (60 mg m-2 i.v.) and vindesine (3 mg m-2 i.v.) on day 1, followed by a 3 day continuous infusion of 5-fluorouracil (800 mg m-2 day-1) starting on day 8. An overall r...

Descripción completa

Detalles Bibliográficos
Autores principales: Nakano, T., Ikegami, H., Nakamura, S., Kawase, T., Nishikawa, H., Yokota, S., Yoshida, M., Tachibana, T., Igarashi, T., Komuta, K., Higashino, K.
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 1996
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2074391/
https://www.ncbi.nlm.nih.gov/pubmed/8624270

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2074391/
https://www.ncbi.nlm.nih.gov/pubmed/8624270

Ejemplares similares